BridgeMD
Efficacy and Safety of Lisocabtagene Maraleucel (liso-cel) as First-Line Therapy in Adults with Transplant-Ineligible Primary Central Nervous System Lymphoma
EU CTIS ID: 2025-521144-38-00
What this study is testing
The main objective of this study is to understand if liso-cel works in patients with newly diagnosed Primary Central Nervous System Lymphoma (PCNSL) who are unable to undergo autologus stem cell transplant (ASCT) by evaluating how well this treatment can stop the cancer from getting worse within one year after treatment is administered.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Participants (18 years or older) with a new diagnosis of PCNSL confirmed by laboratory tests will take part in the study.
- To be enrolled in the study, participants cannot be eligible for ASCT, must be a good fit for receiving a treatment plan that includes HD-MTX.
- Participants must have previously been treated only with standard treatments, and before agreeing to join the study, the signs of their cancer must be either completely gone or mostly gone.
- They must have an ECOG performance score of 0 to 2, which means they are able to carry out their daily activities but may not be able to work.
You likely can't join if
- Participants can't have a type of brain cancer that spread from another part of the body, or any serious medical condition or laboratory test result that would make it too risky for them to join the study, based on the doctor's judgment.
- Participants may not have had another type of cancer that has not been in remission (no signs of cancer) for at least 2 years.
- Other exclusion reasons may include previous treatments, having certain infections that are not under control or an active autoimmune disease that requires treatment to suppress the immune system.
The study team makes the final eligibility decision.
Where it's taking place
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.